<DOC>
	<DOC>NCT01517555</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to to investigate if there is a drug-drug interaction between liraglutide and paracetamol (BenuronÂ®) and to investigate the effect of liraglutide on post prandial glucose.</brief_summary>
	<brief_title>Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Type 2 diabetes mellitus Diettreated subjects with type 2 diabetes with HbA1c 7.59.5 % Subjects with type 2 diabetes in oral antidiabetic drug (OAD) monotherapy treated with metformin or alphaglucosidase inhibitors with HbA1c 7.09.5% Body mass index (BMI) 18.540 kg/m^2 Subjects should have a stable body weight for at least 3 months prior to screening (as judged by the Investigator) Impaired liver function Impaired renal function Clinically significant active cardiovascular disease including history of myocardial infarction within the last 6 months and/or heart failure Any clinically significant abnormal ECG (electrocardiogram) Uncontrolled treated/untreated hypertension Recurrent severe hypoglycaemia as judged by the Investigator Active hepatitis B and/or active hepatitis C Positive human immunodeficiency virus (HIV) antibodies Known or suspected allergy to trial product(s) or related products</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>